{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:05:07Z","timestamp":1792325107115,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T00:00:00Z","timestamp":1615420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00393-021-00974-9","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T17:02:42Z","timestamp":1615482162000},"page":"314-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Kortisonfreie Rheumatologie\u00a0\u2013 Vaskulitiden","Cortisone-free rheumatology\u2014Vasculitides"],"prefix":"10.1007","volume":"80","author":[{"given":"Julia U.","family":"Holle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Moosig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"1","key":"974_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich\u00a0B, Agueda\u00a0A, Monti\u00a0S, Buttgereit\u00a0F, De Boysson\u00a0H, Brouwer\u00a0E et\u00a0al (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19\u2013130","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"974_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"77","author":"JH Stone","year":"2017","unstructured":"Stone\u00a0JH, Tuckwell\u00a0K, Dimonaco\u00a0S, Klearman\u00a0M, Aringer\u00a0M, Blockmans\u00a0D et al (2017) Trial of tocilizumab in giant-cell arteritis. N\u00a0Engl J Med 77(4):317\u2013328","journal-title":"N Engl J Med"},{"issue":"8","key":"974_CR3","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"AD Mahr","year":"2007","unstructured":"Mahr\u00a0AD, Jover\u00a0JA, Spiera\u00a0RF, Hern\u00e1ndez-Garc\u00eda\u00a0C, Fern\u00e1ndez-Guti\u00e9rrez\u00a0B, LaValley\u00a0MP et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum 56(8):2789\u20132797","journal-title":"Arthritis Rheum"},{"issue":"S10","key":"974_CR4","first-page":"abstract 1838","volume":"71","author":"J Stone","year":"2019","unstructured":"Stone\u00a0J, Spotswood\u00a0H, Unizony\u00a0S, Aringer\u00a0M, Blockmans\u00a0DBE et al (2019) Time to flare in patients with new-onset versus relapsing giant cell arteritis treated with Tocilizumab or placebo plus prednisone tapering: 3\u2011year results from a\u00a0randomized controlled phase 3 trial. Arthritis Rheumatol 71(S10):abstract 1838","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 3","key":"974_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"6","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, de Groot\u00a0K, Hellmich\u00a0B, Holle\u00a0JU, Kneitz\u00a0C et al (2017) S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z\u00a0Rheumatol 6(Suppl 3):77\u2013104","journal-title":"Z Rheumatol"},{"issue":"9","key":"974_CR6","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates\u00a0M, Watts\u00a0RA, Bajema\u00a0IM, Cid\u00a0MC, Crestani\u00a0B, Hauser\u00a0T et al (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75(9):1583\u20131594","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"974_CR7","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot\u00a0K, Rasmussen\u00a0N, Bacon\u00a0PA, Tervaert\u00a0JWC, Feighery\u00a0C, Gregorini\u00a0G et al (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52(8):2461\u20132469","journal-title":"Arthritis Rheum"},{"issue":"10","key":"974_CR8","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/art.34547","volume":"64","author":"M Faurschou","year":"2012","unstructured":"Faurschou\u00a0M, Westman\u00a0K, Rasmussen\u00a0N, De Groot\u00a0K, Flossmann\u00a0O, H\u00f6glund\u00a0P et al (2012) Long-term outcome of a\u00a0randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(10):3472\u20133477","journal-title":"Arthritis Rheum"},{"issue":"10","key":"974_CR9","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras\u00a0A, Pagnoux\u00a0C, Haubitz\u00a0M, De Groot\u00a0K, Puechal\u00a0X, Tervaert\u00a0JWC et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76(10):1662\u20131668","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"974_CR10","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/acr.20176","volume":"62","author":"M Walsh","year":"2010","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Mahr\u00a0A, Jayne\u00a0D (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62(8):1166\u20131173","journal-title":"Arthritis Care Res"},{"issue":"5","key":"974_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks\u00a0U, Merkel\u00a0PA, Seo\u00a0P, Spiera\u00a0R, Langford\u00a0CA, Hoffman\u00a0GS et al (2013) Efficacy of remission-induction regimens for ANCA-associated vasculitis. N\u00a0Engl J Med 369(5):417\u2013427","journal-title":"N Engl J Med"},{"issue":"8","key":"974_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","volume":"150","author":"K De Groot","year":"2009","unstructured":"De Groot\u00a0K, Harper\u00a0L, Jayne\u00a0DRW, Felipe\u00a0L, Suarez\u00a0F, Gregorini\u00a0G (2009) Annals of internal medicine pulse versus daily oral cyclophosphamide for induction of remission. Ann Intern Med 150(8):670\u2013680","journal-title":"Ann Intern Med"},{"issue":"9","key":"974_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","volume":"143","author":"SL Hogan","year":"2005","unstructured":"Hogan\u00a0SL, Falk\u00a0RJ, Hyunsook\u00a0C, Cai\u00a0J, Jennette\u00a0CE, Jennette\u00a0JC et\u00a0al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143(9):621\u2013623","journal-title":"Ann Intern Med"},{"issue":"2","key":"974_CR14","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh\u00a0M, Flossmann\u00a0O, Berden\u00a0A, Westman\u00a0K, H\u00f6glund\u00a0P, Stegeman\u00a0C et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64(2):542\u2013548","journal-title":"Arthritis Rheum"},{"issue":"1","key":"974_CR15","first-page":"1","volume":"9","author":"MD Morgan","year":"2017","unstructured":"Morgan\u00a0MD, Szeto\u00a0M, Walsh\u00a0M, Jayne\u00a0D, Westman\u00a0K, Rasmussen\u00a0N et al (2017) Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a\u00a0reduced risk of relapse. Arthritis Res Ther 9(1):1\u20137","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"974_CR16","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1002\/art.34562","volume":"64","author":"S Lionaki","year":"2012","unstructured":"Lionaki\u00a0S, Blyth\u00a0ER, Hogan\u00a0SL, Hu\u00a0Y, Senior\u00a0BA, Jennette\u00a0CE et\u00a0al (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64(10):3452\u20133462","journal-title":"Arthritis Rheum"},{"issue":"8","key":"974_CR17","doi-asserted-by":"publisher","first-page":"e6083","DOI":"10.1097\/MD.0000000000006083","volume":"96","author":"R Solans-Laqu\u00e9","year":"2017","unstructured":"Solans-Laqu\u00e9\u00a0R, Fraile\u00a0G, Rodriguez-Carballeira\u00a0M, Caminal\u00a0L, Castillo\u00a0MJ, Mart\u00ednez-Valle\u00a0F et al (2017) Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine 96(8):e6083","journal-title":"Medicine"},{"issue":"S10","key":"974_CR18","first-page":"abstract 2624.","volume":"71","author":"P Charles","year":"2019","unstructured":"Charles\u00a0P, Perrodeau\u00a0E, Samson\u00a0M, Bonnotte\u00a0B, Hamidou\u00a0MAC et al (2019) Comparison between long-term and conventional Rituximab-maintenance treatments: results of a\u00a0placebo-controlled randomized trial. Arthritis Rheum 71(S10):abstract 2624.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"974_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","volume":"54","author":"J Robson","year":"2015","unstructured":"Robson\u00a0J, Doll\u00a0H, Suppiah\u00a0R, Flossmann\u00a0O, Harper\u00a0L, H\u00f6glund\u00a0P et al (2015) Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: Long-term data from the European Vasculitis Study Group trials. Rheumatology 54(3):471\u2013481","journal-title":"Rheumatology"},{"issue":"7","key":"974_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA, Szpirt\u00a0WM, Puechal\u00a0X, Fujimoto\u00a0S et al (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N\u00a0Engl J Med 382(7):622\u2013631","journal-title":"N Engl J Med"},{"issue":"9","key":"974_CR21","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne\u00a0DRW, Bruchfeld\u00a0AN, Harper\u00a0L, Schaier\u00a0M, Venning\u00a0MC, Hamilton\u00a0P et al (2017) Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J\u00a0Am Soc Nephrol 28(9):2756\u20132767","journal-title":"J Am Soc Nephrol"},{"key":"974_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, Bekker\u00a0P for the ADVOCATE Study Group (2021) Avacopan for the treatment of ANCA-associated vasculitis. New Engl J Med 384:599\u2013609","journal-title":"New Engl J Med"},{"issue":"19","key":"974_CR23","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Karras\u00a0A, Khouatra\u00a0C, Auma\u00eetre\u00a0O, Cohen\u00a0P et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N\u00a0Engl J Med 371(19):1771\u20131780","journal-title":"N Engl J Med"},{"issue":"8","key":"974_CR24","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles\u00a0P, Terrier\u00a0B, Perrodeau \u00c9, Cohen\u00a0P, Faguer\u00a0S, Huart\u00a0A et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a\u00a0multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77(8):1144\u20131150","journal-title":"Ann Rheum Dis"},{"key":"974_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh\u00a0M, Pagnoux\u00a0C, Baldini\u00a0C, Bel\u00a0E, Bottero\u00a0P, Cottin\u00a0V et\u00a0al (2015) Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26:545\u2013553","journal-title":"Eur J Intern Med"},{"key":"974_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond\u00a0C, Pagnoux\u00a0C, Khellaf\u00a0M, Cordier\u00a0JF, Hamidou\u00a0M, Viallard\u00a0JF et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-strauss) clinical characteristics and long-term followup of the 383 patients enrolled in the French vasculitis study group cohort. Arthritis Rheum 65:270\u2013281","journal-title":"Arthritis Rheum"},{"key":"974_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig\u00a0F, Bremer\u00a0JP, Hellmich\u00a0B, Holle\u00a0JU, Holl-Ulrich\u00a0K, Laudien\u00a0M et al (2013) A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg\u2013Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 72:1011\u20131017","journal-title":"Ann Rheum Dis"},{"key":"974_CR28","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Puechal","year":"2017","unstructured":"Puechal\u00a0X, Pagnoux\u00a0C, Baron\u00a0G, Quemeneur\u00a0T, Neel\u00a0A, Agard\u00a0C et al (2017) Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors. Arthritis Rheum 69:2175\u20132186","journal-title":"Arthritis Rheum"},{"key":"974_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad\u00a0AJ, Hot\u00a0A, Arndt\u00a0F, Moosig\u00a0F, Guerry\u00a0MJ, Amudala\u00a0N et\u00a0al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). Ann Rheum Dis 75:396\u2013401","journal-title":"Ann Rheum Dis"},{"key":"974_CR30","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira\u00a0V, Mohammad\u00a0AJ, Jones\u00a0RB, Smith\u00a0R, Jayne\u00a0D (2019) Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5:e905","journal-title":"RMD Open"},{"issue":"5","key":"974_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig\u00a0F, Gross\u00a0WL, Herrmann\u00a0K, Bremer\u00a0JP, Hellmich\u00a0B (2011) Targeting interleukin\u20115 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 155(5):341\u2013343","journal-title":"Ann Intern Med"},{"key":"974_CR32","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"M Wechsler","year":"2017","unstructured":"Wechsler\u00a0M, Akuthota\u00a0P, Jayne\u00a0D, Khoury\u00a0P, Klion\u00a0A, Langford\u00a0CA et\u00a0al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N\u00a0Engl J Med 376:1921\u20131932","journal-title":"N Engl J Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00974-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-00974-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-00974-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T09:09:47Z","timestamp":1620119387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-00974-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-00974-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"15 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.U.\u00a0Holle erhielt Honorare f\u00fcr Referentent\u00e4tigkeiten f\u00fcr die Firmen Roche und Chugai. F.\u00a0Moosig erhielt Honorare f\u00fcr Referentent\u00e4tigkeiten f\u00fcr die Firmen Roche und Chugai sowie Honorare von GSK f\u00fcr seine T\u00e4tigkeit in einem Advisory Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}